Diabetes News and Research

Latest Diabetes News and Research

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Eli Lilly and Company and Incyte Corporation announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month dose-ranging Phase II trial for rheumatoid arthritis.

21 Dec 2009

Medical experts recognize surgery as legitimate and effective treatment for type 2 diabetes

A first-of-its-kind consensus statement by 50 medical experts from around the world has pronounced surgery to be a legitimate and effective treatment for type 2 diabetes, bringing the procedure a significant step closer to wider use and acceptance.

21 Dec 2009

Vitamin D rich food source for winter - Wild Alaska salmon

Today is the shortest day of the year. During the dark winter months, sunlight can be an insufficient source of vitamin D which is vital for the absorption of calcium and phosphorous. Low vitamin D levels have recently been linked to a greater chance of developing diseases including diabetes and heart disease, several cancers and the common cold.

21 Dec 2009

Direct primary care amendment may offer affordable health care options for Americans

The U.S. Senate today made an important step that could expand health care coverage to more Americans while simultaneously reducing costs. The Manager's Amendment, introduced by Senator Harry Reid (D-Nev.) this morning, includes a provision that would allow flat-fee direct primary care practices, in which patients pay a flat fee for primary and preventive care, to compete in the proposed insurance exchange. This will provide Americans more affordable health care options beyond traditional insurance.

21 Dec 2009

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

Medica's clinic-based chronic care management program delivers promising results

Medica’s clinic-based chronic care management program with six clinic partners shows that focusing on care coordination is beginning to deliver promising results. A recent program evaluation reported that members participating in the clinical pilots had 1 percent more doctor visits and 3 percent more prescription fills than members with similar conditions seen in traditional clinic settings.

19 Dec 2009

Annual diabetes Consumer Guide to be published in the January 2010 issue by Diabetes Forecast

When shopping for a new cell phone or even a car, there are dozens of features to explore and choices to make. The same is true of shopping for medical products that will help manage a chronic disease.

19 Dec 2009

Diabetes patients at higher risk from glaucoma

An estimated 3 million Americans have glaucoma, which can stealthily cause vision loss even before people realize they have the disease. People with diabetes face special risks from glaucoma. This January during Glaucoma Awareness Month, through its EyeSmart™ campaign, the American Academy of Ophthalmology in partnership with the American Glaucoma Society and the Glaucoma Research Foundation, remind Americans that knowing your glaucoma risks can save your sight and that people with diabetes need to be extra-vigilant.

19 Dec 2009

CLIAWAIVED.COM expands its business into GPO market by signing the first major GPO

CLIAWAIVED.COM, Inc., the leading Internet-based, multi-line distributor of point-of-care CLIA Waived Diagnostic tests, medical products and physician office supplies, today announced the planned expansion of their business into the GPO (Group Purchasing Organization) market with the signing of their first major GPO, representing nearly 700 physician offices and 7000+ doctors.

19 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

MinuteClinic medical clinics in select CVS/pharmacy stores offer H1N1 vaccinations

MinuteClinic medical clinics in select CVS/pharmacy stores throughout Maryland, North Carolina and Tennessee are now offering H1N1 vaccinations on demand seven days a week with no appointment necessary.

19 Dec 2009

UCSF/SFGH project to improve health outcomes among diabetes patients honored

A UCSF/San Francisco General Hospital project that used a novel communication tool to improve health outcomes among diabetes patients was honored recently with a quality leadership award from the California Health Care Safety Net Institute.

18 Dec 2009

Liberator Medical Holdings reports record net revenues for fiscal year 2009

Liberator Medical Holdings, Inc. announced net revenues for fiscal year 2009 of $25,818,000, representing an increase of $16,268,000, or 170.3%, compared with fiscal year 2008. The increase in sales occurred in the mail order segment of its business. The increase was due to a substantial direct-response advertising campaign to obtain new mail order customers.

18 Dec 2009

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, announced today that it is setting up Niacinamide and 3-Cyanopyridine plant of 10,000 TPA each, expected to be ready by end of 2010.

18 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

White paper discussing investment opportunities related to the U.S. healthcare reform released

Rockefeller and Company - a leading global wealth management firm serving high-net-worth individuals, families, trusts, foundations and endowments - today released "The Investment Opportunities in Healthcare Reform," a white paper discussing the compelling investment opportunities related to the U.S. healthcare reform initiative.

18 Dec 2009

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

Australia's regenerative medicine company, Mesoblast Limited, today announced significant preclinical trial results showing that the proprietary adult stem cell platform could be an effective treatment for diabetes.

18 Dec 2009

2010 Dr. Paul Janssen Award for Biomedical Research open for nomination

The Dr. Paul Janssen Award for Biomedical Research has opened the 2010 call for nominations. The $100,000 Award recognizes individuals whose efforts have made significant transformational contributions towards the improvement of human health. Nomination forms are available at pauljanssenaward.com and will be accepted until February 15, 2010.

18 Dec 2009

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin A1c levels.

18 Dec 2009

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Immuno Laboratories, a leading provider of food and environmental allergy testing services, announced an agreement with Three Rivers Provider Network (TRPN), the largest and fastest growing proprietary Preferred Provider Organization (PPO) network in the United States.

18 Dec 2009

Diabetes News and Research

Latest Diabetes News and Research

Eli Lilly, Incyte announce collaboration for development and commercialization of INCB28050 oral inhibitor

Medical experts recognize surgery as legitimate and effective treatment for type 2 diabetes

Vitamin D rich food source for winter - Wild Alaska salmon

Direct primary care amendment may offer affordable health care options for Americans

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Medica's clinic-based chronic care management program delivers promising results

Annual diabetes Consumer Guide to be published in the January 2010 issue by Diabetes Forecast

Diabetes patients at higher risk from glaucoma

CLIAWAIVED.COM expands its business into GPO market by signing the first major GPO

InHealth to further understand socioeconomic impact of medical devices and diagnostics

MinuteClinic medical clinics in select CVS/pharmacy stores offer H1N1 vaccinations

UCSF/SFGH project to improve health outcomes among diabetes patients honored

Liberator Medical Holdings reports record net revenues for fiscal year 2009

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

White paper discussing investment opportunities related to the U.S. healthcare reform released

Proprietary adult stem cell platform, an effective treatment for diabetes, shows study

2010 Dr. Paul Janssen Award for Biomedical Research open for nomination

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

Immuno Laboratories and TRPN sign agreement to reduce chronic illness

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Diabetes News and Research

Latest Diabetes News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in